Christina Louise Costantino, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pneumonectomy | 2 | 2021 | 1094 | 0.900 |
Why?
|
| Thoracic Outlet Syndrome | 1 | 2021 | 85 | 0.690 |
Why?
|
| Ribs | 1 | 2021 | 252 | 0.680 |
Why?
|
| Esophageal Achalasia | 1 | 2020 | 91 | 0.680 |
Why?
|
| Gastrectomy | 3 | 2019 | 663 | 0.630 |
Why?
|
| Tracheal Neoplasms | 1 | 2018 | 124 | 0.620 |
Why?
|
| Stomach Neoplasms | 4 | 2021 | 1333 | 0.610 |
Why?
|
| Laparoscopy | 2 | 2020 | 2151 | 0.590 |
Why?
|
| Trachea | 2 | 2021 | 1076 | 0.560 |
Why?
|
| Laryngostenosis | 1 | 2017 | 161 | 0.530 |
Why?
|
| Laryngectomy | 1 | 2017 | 248 | 0.530 |
Why?
|
| Deglutition Disorders | 1 | 2020 | 605 | 0.480 |
Why?
|
| Tracheostomy | 1 | 2017 | 401 | 0.470 |
Why?
|
| Deoxycytidine Kinase | 2 | 2010 | 12 | 0.380 |
Why?
|
| Antigens, Surface | 3 | 2010 | 1663 | 0.380 |
Why?
|
| Deoxycytidine | 2 | 2010 | 826 | 0.320 |
Why?
|
| Lung Neoplasms | 5 | 2023 | 13102 | 0.320 |
Why?
|
| RNA-Binding Proteins | 3 | 2010 | 1903 | 0.270 |
Why?
|
| Carcinoma, Pancreatic Ductal | 3 | 2009 | 1634 | 0.240 |
Why?
|
| General Surgery | 1 | 2015 | 1636 | 0.230 |
Why?
|
| Pancreatic Neoplasms | 6 | 2010 | 5256 | 0.200 |
Why?
|
| Fundoplication | 1 | 2020 | 138 | 0.170 |
Why?
|
| Nitrogen | 1 | 2020 | 344 | 0.170 |
Why?
|
| Sexual Harassment | 1 | 2019 | 79 | 0.170 |
Why?
|
| Thoracic Surgery, Video-Assisted | 1 | 2021 | 273 | 0.160 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 2 | 2009 | 109 | 0.160 |
Why?
|
| Smoking | 1 | 2015 | 8987 | 0.160 |
Why?
|
| Bronchi | 1 | 2021 | 840 | 0.150 |
Why?
|
| Antimetabolites, Antineoplastic | 3 | 2010 | 640 | 0.150 |
Why?
|
| Thoracic Surgical Procedures | 1 | 2021 | 342 | 0.140 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2019 | 1770 | 0.140 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2021 | 3479 | 0.140 |
Why?
|
| New Orleans | 1 | 2015 | 27 | 0.130 |
Why?
|
| Diphosphonates | 1 | 2020 | 623 | 0.130 |
Why?
|
| Treatment Outcome | 5 | 2021 | 63114 | 0.130 |
Why?
|
| Neoadjuvant Therapy | 3 | 2021 | 2728 | 0.120 |
Why?
|
| Robotics | 1 | 2021 | 899 | 0.110 |
Why?
|
| Lymph Node Excision | 1 | 2019 | 1261 | 0.110 |
Why?
|
| Vitamin K 2 | 1 | 2009 | 47 | 0.090 |
Why?
|
| Early Detection of Cancer | 2 | 2023 | 3086 | 0.090 |
Why?
|
| Vitamin K 1 | 1 | 2009 | 48 | 0.090 |
Why?
|
| Thymidylate Synthase | 1 | 2009 | 75 | 0.080 |
Why?
|
| Esophageal Neoplasms | 1 | 2019 | 1583 | 0.080 |
Why?
|
| Immunologic Surveillance | 1 | 2009 | 93 | 0.080 |
Why?
|
| Carcinoma, Adenosquamous | 1 | 2009 | 68 | 0.080 |
Why?
|
| Smad4 Protein | 1 | 2009 | 163 | 0.080 |
Why?
|
| Diphtheria Toxin | 1 | 2008 | 255 | 0.080 |
Why?
|
| Education, Medical | 1 | 2019 | 1721 | 0.080 |
Why?
|
| Humans | 22 | 2023 | 744343 | 0.070 |
Why?
|
| Cytarabine | 1 | 2009 | 692 | 0.070 |
Why?
|
| History, 20th Century | 1 | 2015 | 2740 | 0.070 |
Why?
|
| Genome, Human | 1 | 2020 | 4420 | 0.070 |
Why?
|
| Caspases | 1 | 2009 | 928 | 0.070 |
Why?
|
| Genes, p53 | 1 | 2009 | 755 | 0.070 |
Why?
|
| RNA, Neoplasm | 1 | 2009 | 769 | 0.070 |
Why?
|
| Boston | 1 | 2018 | 9313 | 0.070 |
Why?
|
| Retrospective Studies | 6 | 2023 | 77449 | 0.070 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2023 | 5221 | 0.060 |
Why?
|
| Time Factors | 3 | 2018 | 40075 | 0.060 |
Why?
|
| Fluorouracil | 1 | 2009 | 1619 | 0.060 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2009 | 5172 | 0.060 |
Why?
|
| Tamoxifen | 1 | 2008 | 981 | 0.060 |
Why?
|
| Cytoplasm | 1 | 2008 | 1539 | 0.060 |
Why?
|
| ras Proteins | 1 | 2009 | 1060 | 0.060 |
Why?
|
| Up-Regulation | 2 | 2009 | 4217 | 0.060 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2009 | 8428 | 0.050 |
Why?
|
| Adult | 4 | 2021 | 214055 | 0.050 |
Why?
|
| Physicians | 1 | 2019 | 4567 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 1 | 2009 | 6314 | 0.050 |
Why?
|
| RNA, Messenger | 3 | 2010 | 13033 | 0.050 |
Why?
|
| Female | 8 | 2021 | 380194 | 0.050 |
Why?
|
| Receptors, Estrogen | 1 | 2008 | 2187 | 0.050 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2008 | 1524 | 0.040 |
Why?
|
| Middle Aged | 6 | 2020 | 213383 | 0.040 |
Why?
|
| Internship and Residency | 1 | 2019 | 5788 | 0.040 |
Why?
|
| Alendronate | 1 | 2020 | 171 | 0.040 |
Why?
|
| Cell Line, Tumor | 6 | 2010 | 16689 | 0.040 |
Why?
|
| Mutation | 3 | 2020 | 29786 | 0.040 |
Why?
|
| Polymorphism, Genetic | 1 | 2009 | 4328 | 0.040 |
Why?
|
| Anastomotic Leak | 1 | 2019 | 162 | 0.040 |
Why?
|
| Membrane Glycoproteins | 1 | 2008 | 3768 | 0.040 |
Why?
|
| Neoplasm Staging | 2 | 2023 | 11031 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2018 | 23338 | 0.040 |
Why?
|
| Drug Delivery Systems | 1 | 2008 | 2219 | 0.040 |
Why?
|
| Nanoparticles | 1 | 2008 | 1905 | 0.040 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2009 | 4554 | 0.030 |
Why?
|
| Postoperative Complications | 1 | 2018 | 15295 | 0.030 |
Why?
|
| Osteoclasts | 1 | 2020 | 729 | 0.030 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2009 | 2988 | 0.030 |
Why?
|
| Survival Rate | 2 | 2021 | 12788 | 0.030 |
Why?
|
| Esophagectomy | 1 | 2019 | 447 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2010 | 10481 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2019 | 1842 | 0.030 |
Why?
|
| Aged | 4 | 2019 | 163280 | 0.030 |
Why?
|
| Apoptosis | 1 | 2009 | 9727 | 0.030 |
Why?
|
| Lung | 2 | 2023 | 9856 | 0.030 |
Why?
|
| Risk Factors | 1 | 2018 | 72290 | 0.030 |
Why?
|
| DNA-Binding Proteins | 1 | 2009 | 9648 | 0.020 |
Why?
|
| Recurrence | 1 | 2023 | 8340 | 0.020 |
Why?
|
| Immunohistochemistry | 3 | 2009 | 11366 | 0.020 |
Why?
|
| Adenocarcinoma | 1 | 2008 | 6364 | 0.020 |
Why?
|
| Melanoma | 1 | 2009 | 5510 | 0.020 |
Why?
|
| Hematopoiesis | 1 | 2020 | 2072 | 0.020 |
Why?
|
| Male | 5 | 2020 | 350118 | 0.020 |
Why?
|
| Skin Neoplasms | 1 | 2009 | 5686 | 0.020 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 2009 | 190 | 0.020 |
Why?
|
| Bone and Bones | 1 | 2020 | 2575 | 0.020 |
Why?
|
| Thymidine | 1 | 2009 | 310 | 0.020 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2009 | 459 | 0.020 |
Why?
|
| Genes, p16 | 1 | 2009 | 157 | 0.020 |
Why?
|
| Uridine | 1 | 2009 | 146 | 0.020 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2009 | 337 | 0.020 |
Why?
|
| HCT116 Cells | 1 | 2009 | 408 | 0.020 |
Why?
|
| Yeasts | 1 | 2009 | 285 | 0.020 |
Why?
|
| GPI-Linked Proteins | 1 | 2008 | 434 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2009 | 625 | 0.020 |
Why?
|
| Tissue Array Analysis | 1 | 2008 | 553 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2009 | 23403 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2009 | 13695 | 0.020 |
Why?
|
| Massachusetts | 1 | 2019 | 8663 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2009 | 1682 | 0.020 |
Why?
|
| Length of Stay | 1 | 2019 | 6309 | 0.020 |
Why?
|
| Patient Readmission | 1 | 2019 | 3114 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2023 | 9239 | 0.020 |
Why?
|
| Drug Resistance | 1 | 2010 | 1609 | 0.020 |
Why?
|
| Cadherins | 1 | 2009 | 907 | 0.020 |
Why?
|
| Registries | 1 | 2019 | 8089 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 4751 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2010 | 5179 | 0.010 |
Why?
|
| Forkhead Transcription Factors | 1 | 2009 | 1613 | 0.010 |
Why?
|
| RNA Interference | 1 | 2010 | 2889 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 19905 | 0.010 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2009 | 1692 | 0.010 |
Why?
|
| HEK293 Cells | 1 | 2010 | 4204 | 0.010 |
Why?
|
| Lymphatic Metastasis | 1 | 2009 | 2924 | 0.010 |
Why?
|
| Cell Cycle | 1 | 2009 | 2967 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2008 | 20822 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 2009 | 3206 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2009 | 4186 | 0.010 |
Why?
|
| Cell Survival | 1 | 2009 | 5882 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2009 | 6171 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2009 | 8436 | 0.010 |
Why?
|
| Protein Binding | 1 | 2010 | 9386 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2009 | 4803 | 0.010 |
Why?
|
| Alleles | 1 | 2009 | 6933 | 0.010 |
Why?
|
| Base Sequence | 1 | 2009 | 12797 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2009 | 10943 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2020 | 40561 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2008 | 5867 | 0.010 |
Why?
|
| Gene Expression | 1 | 2009 | 7799 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2009 | 18111 | 0.010 |
Why?
|
| Genotype | 1 | 2009 | 12951 | 0.010 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2009 | 5535 | 0.010 |
Why?
|
| Mice | 1 | 2020 | 81183 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2008 | 9438 | 0.010 |
Why?
|
| Models, Biological | 1 | 2008 | 9583 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2009 | 7880 | 0.010 |
Why?
|
| Colorectal Neoplasms | 1 | 2009 | 6773 | 0.010 |
Why?
|
| Animals | 1 | 2020 | 168757 | 0.000 |
Why?
|